Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 - PubMed (original) (raw)

Clinical Trial

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1

Hari S Conjeevaram et al. Gastroenterology. 2006 Aug.

Abstract

Background & aims: Compared with Caucasian Americans (CA), African Americans (AA) with chronic hepatitis C are less likely to respond to interferon-based antiviral therapy.

Methods: In a multicenter treatment trial, 196 AA and 205 CA treatment-naive patients with hepatitis C virus (HCV) genotype 1 infection were treated with peginterferon alfa-2a (180 microg/wk) and ribavirin (1000-1200 mg/day) for up to 48 weeks. The primary end point was sustained virologic response (SVR).

Results: Baseline features were similar among AA and CA, including HCV-RNA levels and histologic severity, but AA had higher body weights, a higher prevalence of diabetes and hypertension, and lower alanine transaminase levels (P < .001 for all). The SVR rate was 28% in AA and 52% in CA (P < .0001). Racial differences in viral responses were evident as early as treatment week 4. Breakthrough viremia was more frequent among AA than CA (13% vs 6%, P = .05); relapse rates were comparable (32% vs 25%, P = .30). Proportions of patients with serious adverse events and dose modifications and discontinuations were similar among AA and CA. In multiple regression analyses, CA had a higher SVR rate than AA (relative risk, 1.96; 95% confidence interval, 1.48-2.60; P < .0001). Other factors independently associated with higher SVR included female sex, lower baseline HCV-RNA level, less hepatic fibrosis, and more peginterferon taken.

Conclusions: AA with chronic hepatitis C genotype 1 have lower rates of virologic response to peginterferon and ribavirin than CA. These differences are not explained by disease characteristics, baseline viral levels, or amount of medication taken.

PubMed Disclaimer

Cited by

Optimum ribavirin exposure overcomes racial disparity in efficacy of peginterferon and ribavirin treatment for hepatitis C genotype 1.
Jin R, Cai L, Tan M, McHutchison JG, Dowling TC, Howell CD. Jin R, et al. Am J Gastroenterol. 2012 Nov;107(11):1675-83. doi: 10.1038/ajg.2012.306. Epub 2012 Oct 23. Am J Gastroenterol. 2012. PMID: 23090351 Free PMC article.
Suppression of ribosomal protein synthesis and protein translation factors by Peg-interferon alpha/ribavirin in HCV patients blood mononuclear cells (PBMC).
Gupta R, Kim S, Taylor MW. Gupta R, et al. J Transl Med. 2012 Mar 22;10:54. doi: 10.1186/1479-5876-10-54. J Transl Med. 2012. PMID: 22436241 Free PMC article.
Treatment responses in Asians and Caucasians with chronic hepatitis C infection.
Yan KK, Guirgis M, Dinh T, George J, Dev A, Lee A, Zekry A. Yan KK, et al. World J Gastroenterol. 2008 Jun 7;14(21):3416-20. doi: 10.3748/wjg.14.3416. World J Gastroenterol. 2008. PMID: 18528940 Free PMC article.
Rapid reversal of innate immune dysregulation in blood of patients and livers of humanized mice with HCV following DAA therapy.
Burchill MA, Roby JA, Crochet N, Wind-Rotolo M, Stone AE, Edwards MG, Dran RJ, Kriss MS, Gale M Jr, Rosen HR. Burchill MA, et al. PLoS One. 2017 Oct 17;12(10):e0186213. doi: 10.1371/journal.pone.0186213. eCollection 2017. PLoS One. 2017. PMID: 29040318 Free PMC article.
Fibrosis progression in African Americans and Caucasian Americans with chronic hepatitis C.
Terrault NA, Im K, Boylan R, Bacchetti P, Kleiner DE, Fontana RJ, Hoofnagle JH, Belle SH; VIRAHEP-C Study Group. Terrault NA, et al. Clin Gastroenterol Hepatol. 2008 Dec;6(12):1403-11. doi: 10.1016/j.cgh.2008.08.006. Epub 2008 Aug 19. Clin Gastroenterol Hepatol. 2008. PMID: 19081528 Free PMC article.

Peginterferon and ribavirin treatment in African American and Caucasian American patients with hepatitis C genotype 1 - PubMed (original) (raw)